Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Nov 11, 2019 (7 years ago)

Lidocaine HCl Injection (Marcaine, Lidocaine, Povidone Iodine)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Presence of Foreign Substance: Foreign material found inside the vial.

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

Lidocaine HCl Injection, USP, 2% 100 mg/5 mL (20 mg/mL), Preservative-Free, packaged in 10 x 5 mL Single Dose Vials per carton, Rx only, Distributed by: AuroMedics Pharma LLC, 279 Princeton-Hightstown Rd., E. Windsor, NJ 08520, NDC 55150-165-05.

Affected NDC 55150-0165-05

Compare with the code on your package — it is the most precise check available.

Drug: Lidocaine

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Lidocaine Hydrochloride
NDC 55150-0165
20 mg/mL Injection, Solution
Epidural|infiltration|intracaudal|perineural
Eugia US LLC Rx
Recalling firm
AuroMedics Pharma LLC
NDC code
55150-165-05
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0573-2020 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Lidocaine recalls

See all
Class II · Moderate risk

Lidocaine Ointment USP

Failed Content Uniformity Specifications. Out of Specification for Assay during analysis at the 24- month long term stability station, at (25¿C,60%RH).

Ongoing Wrong potency / content Sun Pharma /Taro D-0848-2026
Class III · Low risk

Lidolog Kit

Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan

Ongoing Labeling / mix-up Asclemed USA Inc. D-0713-2026

Other recalls by AuroMedics Pharma LLC

All 2019 recalls
Class II · Moderate risk

Acyclovir Sodium Injection

Presence of Particulate Matter: Customer complaint for a dark red, brown and black particulate floating inside vial.

Completed Particulate / foreign matter AuroMedics Pharma LLC NDC 55150-154-10 D-0013-2023